CL2 Linker

• CAT Number: I018023
• CAS Number: 2270986-66-6
• Molecular Formula: C₆₈H₁₀₃N₁₁O₂₂
• Molecular Weight: 1426.61
• Purity: ≥95%
• Target: ADC Linker
• IUPAC Name: (3-hydroxy-2-oxopropyl) N-[2-[[4-[[(2S)-2-[[(2S)-2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-phenylpropanoyl]amino]-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]amino]phenyl]methoxycarbonyl-methylamino]ethyl]-N-methylcarbamate
• InChI: InChI=1S/C68H103N11O22/c1-68(2,3)101-65(88)69-25-12-11-16-57(63(86)71-54-20-18-53(19-21-54)50-99-66(89)76(4)27-28-77(5)67(90)100-51-56(81)49-80)73-64(87)58(46-52-14-8-6-9-15-52)72-60(83)24-30-91-32-34-93-36-38-95-40-42-97-44-45-98-43-41-96-39-37-94-35-33-92-31-29-78-48-55(74-75-78)47-70-59(82)17-10-7-13-26-79-61(84)22-23-62(79)85/h6,8-9,14-15,18-23,48,57-58,80H,7,10-13,16-17,24-47,49-51H2,1-5H3,(H,69,88)(H,70,82)(H,71,86)(H,72,83)(H,73,87)/t57-,58-/m0/s1
• InChIKey: BGFZCTPREVDQQQ-YQOHNZFASA-N
• SMILES: CC(C)(C)OC(=O)NCCCC[C@@H](C(=O)NC1=CC=C(C=C1)COC(=O)N(C)CCN(C)C(=O)OCC(=O)CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCN3C=C(N=N3)CNC(=O)CCCCCN4C(=O)C=CC4=O

CL2 Linker（Cat No.:I018023）is a chemical compound commonly used in bioconjugation and drug delivery applications, particularly in the development of antibody-drug conjugates (ADCs). The CL2 Linker is designed to connect the cytotoxic drug to an antibody, ensuring targeted delivery to cancer cells. It typically includes a cleavable bond that breaks under specific conditions, releasing the drug at the desired site of action. The CL2 Linker enhances the efficacy of treatments by reducing systemic toxicity while increasing drug concentration at the tumor site. It is part of ongoing research for improving cancer therapies with more precise targeting mechanisms.

Reference

[1]. Moon SJ, et al. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008 Nov 13;51(21):6916-26.[2]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69.